2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1355

Subcutaneous Administration Of Methotrexate With a Prefilled Autoinjector Pen Results In a Higher Relative Bioavailability Compared To Oral Administration Of Methotrexate
Abstract Number: 1475

Subcutaneous Delivery Of Methotrexate Is Associated With Improved Treatment Survival Compared To Oral Administration For The Initial Treatment Of Patients With Early Rheumatoid Arthritis
Abstract Number: 126

Subgrouping Of Rheumatoid Arthritis Patients Based On Pain, Fatigue, Inflammation and Psychosocial Factors
Abstract Number: 968

Success Of Educational Intervention In Improving The Management Of Rheumatoid Arthritis
Abstract Number: 1447

Success Rate Of 5-Or-More-Week Extended-Interval Therapy With Tocilizumab In Rheumatoid Arthritis Patients In Routine Practice
Abstract Number: 1354

Successful Self-Administration Of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector Pen
Abstract Number: 112

Sugar-Sweetened Soft Drink Consumption and Risk Of Developing Rheumatoid Arthritis In Women
Abstract Number: 2619

Suicidal Ideation Among Patients With Behcet’s Syndrome
Abstract Number: 2716

Support For Psychological State May Be Effective to Attain Remission Of Boolean-Based Definition Of Patient Global Assessment In Patients With Rheumatoid Arthritis
Abstract Number: 1836

Suppression Of HDAC5 Expression By Inflammatory Cytokines Is Required To Promote CXCL Chemokine Production In RA FLS
Abstract Number: 1156

Suppression Of Immune Responses and Joint Inflammation By Myeloid-Derived Suppressor Cells In a T Cell-Dependent Mouse Model Of Rheumatoid Arthritis
Abstract Number: 2428

Suppression Of Tumor Necrosis Factor Receptor Associated Factor (TRAF) 6 Attenuates The Proinflammatory Effect Of Rheumatoid Arthritis Fibroblast-Like Synoviocytes
Abstract Number: 44

Suppressor Of Cytokine Signaling 3 Negatively Modulates Leptin-Mediated Catabolic and Proinflammatory Effects In Cartilage – New Potential Mechanism To Target Obesity-Induced Osteoarthritis
Abstract Number: 770

Suppressor Of Cytokine Signaling-3 Is a Critical Regulator Of gp130 Cytokine Signaling In Articular Chondrocytes
Abstract Number: 1090

Suprascapular Nerve Block For Shoulder Pain In The First Year After Stroke: A Randomised Controlled Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].